Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (7): 807-811.
DOI: 10.19803/j.1672-8629.2022.07.26
LI Yanming1,2, ZHAO Zhigang1,*
Received:
2020-09-04
Online:
2022-07-15
Published:
2022-07-12
CLC Number:
LI Yanming, ZHAO Zhigang. Evidence-based ibrutinib-related adverse reactions and pharmaceutical care[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 807-811.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.2022.07.26
[1] SIVINA M, KREITMAN RJ, ARONS E, et al.The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach[J]. Br J Haematol, 2014, 166(2): 177-188. [2] WANG J, LIU X, HONG Y, et al.Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma[J]. J Exp Clin Canc Res, 2017, 36(1): 96. [3] SOUSSAIN C, CHOQUET S, BLONSKI M, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) andthe French oculo-cerebral lymphoma (LOC) network[J]. Eur J Cancer, 2019, (8)117: 121-130. [4] RICHARDSON PG, BENSINGER WI, HUFF CA, et al.Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results[J]. Br J Haematol, 2018, 180(6): 821-830. [5] AL-TOUBAH T, SCHELL MJ, CIVES M, et al.A phase ii study of ibrutinib in advanced neuroendocrine neoplasms[J]. Neuroend-ocrinology, 2020, 110(5): 377-383. [6] HOU K, YU Z, JIA Y, et al.Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: a single-arm meta-analysis[J]. Crit Rev Oncol Hematol, 2020, 152(8): 103010. [7] STEPHENS DM, BYRD JC.How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia[J]. Blood, 2019, 133(12): 1298-1307. [8] ALLOUCHERY M, TOMOWIAK C, GUIDEZ S, et al.Patterns of use and safety of ibrutinib in real-life practice[J]. Br J Clin Pharmacol, 2021, 87(3): 895-904. [9] BYRD JC, FURMAN RR, COUTRE SE, et al.Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib[J]. Blood, 2015, 125(16): 2497-2506. [10] National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5[R/OL].(2017-11-27)[2020-06-30]. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. [11] BROWN JR, MOSLEHI J, EWER MS, et al.Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis[J]. Br J Haematol, 2019, 184(4): 558-569. [12] MOCK J, KUNK PR, PALKIMAS S, et al.Risk of major bleeding with ibrutinib[J]. Clin Lymphoma Myeloma Leuk, 2018, 18(11):755-761. [13] CALDEIRA D, ALVES D, COSTA J, et al.Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis[J]. PLoS One, 2019, 14(2): e0211228. [14] BROWN JR, MOSLEHI J, O'BRIEN S, et al. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials[J]. Haematologica,2017, 102(10): 1796-1805. [15] BYRD JC, FURMAN RR, COUTRE SE, et al.Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia[J]. N Engl J Med, 2013, 369(1): 32-42. [16] BARR PM, ROBAK T, OWEN C, et al.Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2[J]. Haematologica, 2018, 103(9): 1502-1510. [17] DICKERSON T, WICZER T, WALLER A, et al.Hypertension and incident cardiovascular events following ibrutinib initiation[J]. Blood, 2019, 134(22): 1919-1928. [18] TILLMAN BF, PAUFF JM, SATYANARAYANA G, et al.Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies[J]. Eur J Haematol, 2018, 100(4): 325-334. [19] VARUGHESE T, TAUR Y, COHEN N, et al.Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer[J].Clin Infect Dis, 2018, 67(5): 687-692. [20] ROGERS KA, LUAY M, ZHAO Q, et al.Incidence and type of opportunistic infections during ibrutinib treatment at a single academic center[J]. Blood, 2017, 130(S1): 830. [21] LIU MY, CAI J, YAO Y, et al.Literature analysis of invasive fungal infections induced by ibrutinib[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2020, 29(9): 647-651. [22] BALL S, DAS A, VUTTHIKRAIVIT W, et al.Risk of infection associated with ibrutinib in patients with b-cell malignancies: a systematic review and meta-analysis of randomized controlled trials[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(2): 87-97. [23] ZHOU Y, LU H, YANG M, et al.Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized trials[J]. Medicine, 2019, 98(33): e16915. [24] BROWN JR, HILLMEN P, O' BRIEN S, et al. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL[J]. Leukemia, 2018, 32(1): 83-91. [25] PAYDAS S.Management of adverse effects/toxicity of ibrutinib[J].Crit Rev Oncol Hematol, 2019, 136: 56-63. [26] SIBAUD V, BEYLOT-BARRY M, PROTIN C, et al.Dermatological toxicities of bruton's tyrosine kinase inhibitors[J]. American Journal of Clinical Dermatology, 2020 21(6): 799-812. [27] IBERRI DJ, KWONG BY, STEVENS LA, et al.Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management[J]. Br J Haematol, 2018, 180(1): 164-166. [28] STEWART J, BAYERS S, VANDERGRIFF T.Self-limiting ibrutinib-induced neutrophilic panniculitis[J]. Am J Dermato-pathol, 2018, 40(2): e28-e29. [29] BITAR C, FAROOQUI MZ, VALDEZ J, et al.Hair and nail changes during long-term therapy with ibrutinib for chronic lymphocytic leukemia[J]. JAMA Dermatol, 2016, 152(6): 698-701. [30] BYRD JC, BROWN JR, O'BRIEN S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia[J]. N Engl J Med, 2014, 371(3): 213-223. [31] BURGER JA, TEDESCHI A, BARR PM, et al.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia[J]. N Engl J Med, 2015, 373(25): 2425-2437. [32] RHODES JM, LORE VA 3rd, MATO AR, et al. Ibrutinib-associated arthralgias/myalgias in patients with chronic lymphocytic leukemia: incidence and impact on clinical outcomes[J]. Clin Lymphoma Myeloma Leuk, 2020, 20(7): 438-444. [33] COUTRE SE, BYRD JC, HILLMEN P, et al.Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies[J]. Blood Adv, 2019, 3(12): 1799-1807. [34] PUŁA A, STAWISKI K, BRAUN M, et al. Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials[J]. Leuk Lymphoma, 2018, 59(5): 1084-1094. [35] HERMAN SE, NIEMANN CU, FAROOQUI M, et al.Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study[J]. Leukemia, 2014, 28(11): 2188-2196. [36] ROGERS KA, RUPPERT AS, BINGMAN A, et al.Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia[J]. Leukemia, 2016, 30(2): 346-350. [37] TAFESH ZH, COLEMAN M, FULMER C, et al.Severe hepatot-oxicity due to ibrutinib with a review of published cases[J]. Case Rep Gastroenterol, 2019, 13(2): 357-363. [38] HERISHANU Y, KATCHMAN H, POLLIACK A.Severe hepatitis B virus reactivation related to ibrutinib monotherapy[J]. Ann Hematol, 2017, 96(4): 689-690. [39] MOLICA S, LEVATO L, MIRABELLI R.Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature[J]. Leuk Lymphoma, 2016, 57(3): 735-737. [40] ATKINSON BT, ELLMEIER W, WATSON SP.Tec regulates platelet activation by GPVI in the absence of Btk[J]. Blood, 2003, 102(10): 3592-3599. [41] CHEN J, KINOSHITA T, GURURAJA T, et al.The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen‐induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC)[J]. European Journal of Haematology, 2018, 101(5): 604-612. [42] MCMULLEN JR, BOEY EJ, OOI JY, et al.Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling[J]. Blood, 2014, 124(25): 3829-3830. [43] JIANG L, LI L, RUAN Y, et al.Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium[J]. Heart Rhythm, 2019, 16(9): 1374-1382. [44] DUBOVSKY JA, BECKWITH KA, NATARAJAN G, et al.Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes[J]. Blood, 2013, 122(15): 2539-2549. [45] KOHRT HE, SAGIV-BARFI I, RAFIQ S, et al.Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity[J]. Blood, 2013, 122(21): 373. [46] ZERBIT J, CHEVRET S, BERNARD S, et al.Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study[J]. Ann Hematol, 2020, 99(7): 1615-1625. [47] SCHEERS E, LECLERCQ L, DE JONG J, et al.Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men[J]. Drug Metab Dispos. 2015, 43(2): 289-297. [48] DE JONG J, SKEE D, MURPHY J, et al.Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants[J].Pharmacology Research & Perspectives, 2015, 3(4): 00156. [49] TREON SP, TRIPSAS CK, MEID K, et al.Ibrutinib in previously treated Waldenström's macroglobulinemia[J]. N Engl J Med, 2015, 372(15): 1430-1440. [50] KAPELIOS CJ, BONOU MS, DIAMANTOPOULOS P, et al.Ibrutinib-related atrial fibrillation: therapeutic challenges[J].Journal of Oncology Pharmacy Practice, 2019, 25(5): 1258-1260. [51] LASICA M, TAM CS.Management of ibrutinib toxicities: a practical guide[J]. Curr Hematol Malig Rep, 2020, 15(3): 177-186. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
[3] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
[4] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
[5] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
[6] | CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215. |
[7] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
[8] | GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19. |
[9] | JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106. |
[10] | CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110. |
[11] | LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974. |
[12] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[13] | PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981. |
[14] | LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006. |
[15] | TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||